Opinion|Videos|July 24, 2024
Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and address concerns they anticipate with the potential approval of BTKis for MS patients and strategies for mitigating these concerns.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- There is only one FDA-approved option for primary progressive multiple sclerosis. What emerging therapies are under investigation for this subtype of MS?
- Discuss the PERSEUS trial, which is evaluating tolebrutinib in primary progressive multiple sclerosis.
- What are the potential adverse effects of BTKis and how should they be monitored for and managed?
- What access concerns do you anticipate with the potential approval of BTKis for patients with MS, and how can they be mitigated?
- Discuss considerations of BTKis in oncology and how these may relate to MS.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
5
